# venBio Partners LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1776382. Source: https://holderbook.com/funds/1776382-venbio-partners-llc/

- Reported value: $519.4M
- Positions: 7
- Weight of the ten largest: 100.0%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $160.6M | 4,643,430 | 30.9% | 22 |
| PARABILIS MEDICINES INC | [PBLS](https://holderbook.com/stocks/PBLS/) | $144.1M | 5,266,697 | 27.8% | 1 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $127.4M | 4,528,408 | 24.5% | 9 |
| ACHIEVE LIFE SCIENCE INC | [ACHV](https://holderbook.com/stocks/ACHV/) | $38.6M | 5,914,720 | 7.4% | 1 |
| ALX ONCOLOGY HLDGS INC | [ALXO](https://holderbook.com/stocks/ALXO/) | $26.7M | 12,884,638 | 5.1% | 24 |
| HARMONY BIOSCIENCES HLDGS IN | [HRMY](https://holderbook.com/stocks/HRMY/) | $17.2M | 472,194 | 3.3% | 24 |
| LYELL IMMUNOPHARMA INC | [LYEL](https://holderbook.com/stocks/LYEL/) | $4.7M | 337,697 | 0.9% | 5 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +22.0% | +14.8% | +7.2% | 100% |
| Q1 2026 | +28.0% | -4.6% | +32.7% | 100% |
| Q4 2025 | +26.2% | +2.4% | +23.8% | 100% |
| Q3 2025 | +46.1% | +7.8% | +38.3% | 100% |
| Q2 2025 | +47.1% | +10.5% | +36.7% | 92% |
| Q1 2025 | -26.1% | -4.6% | -21.5% | 100% |
| Q4 2024 | -12.9% | +2.1% | -15.1% | 100% |
| Q3 2024 | -18.3% | +5.4% | -23.7% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $519.4M | 7 |
| Q1 2026 | $280.6M | 6 |
| Q4 2025 | $216.3M | 6 |
| Q3 2025 | $176.4M | 6 |
| Q2 2025 | $114.8M | 6 |
| Q1 2025 | $123.6M | 7 |
| Q4 2024 | $170.7M | 7 |
| Q3 2024 | $194.3M | 6 |
| Q2 2024 | $231.5M | 6 |
| Q1 2024 | $281.9M | 5 |
| Q4 2023 | $667.2M | 7 |
| Q3 2023 | $352.7M | 8 |